Showing results (1-10 of 159) with videos related to
Sort By:
Pageof 16
Blood|December 17, 2009
FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AMLKeith W Pratz, Takashi Sato, Kathleen M Murphy, et al.British Journal of Haematology|December 23, 2024
Advancing the outcomes of AML out of antecedent MPN by targeting mutated IDH1Keith W PratzHematology. American Society of Hematology. Education Program|December 9, 2022
Optimizing outcomes in secondary AMLAndrew Matthews, Keith W PratzJournal of the National Comprehensive Cancer Network : JNCCN|July 9, 2017
Role of Alternative Donor Allogeneic Transplants in the Therapy of Acute Myeloid LeukemiaHany Elmariah, Keith W PratzCurrent Drug Targets|April 8, 2010
Bench to bedside targeting of FLT3 in acute leukemiaKeith W Pratz, Mark J LevisLeukemia & Lymphoma|June 3, 2017
Acute myeloid leukemia in the elderly: therapeutic options and choiceJonathan A Webster, Keith W PratzCurrent Opinion in Hematology|January 29, 2014
Will FLT3 inhibitors fulfill their promise in acute meyloid leukemia?Keith W Pratz, Selina M LugerAmerican Journal of Hematology|February 17, 2025
Frontline Therapy of AML in the Fit and Younger Population-Incorporating Molecularly Targeted AgentsKeith W Pratz, Harry P ErbaCancer Journal (Sudbury, Mass.)|January 24, 2022
Incorporation of FLT3 Inhibitors Into the Treatment Regimens for FLT3 Mutated Acute Myeloid Leukemia: The Case for Total TherapyAlexander E Perl, Keith W PratzPageof 16